 SAN DIEGO, Aug. 12, 2021 PRNewswire -- Viracta Therapeutics, Inc. Nasdaq: VIRX, a precision oncology company targeting virus-associated malignancies, today announced financial results for the second quarter of 2021 and provided clinical and corporate updates. We entered the second half of the year with strong momentum thanks to the completion of key milestones across our pipeline, said Ivor Royston, M.D. 